HMG-CoA reductase inhibitors reduce IκB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 5, 2005, Pages 468-475

  Ortego, Monica ^a   Gómez Hernández, Almundena ^a   Vidal, Cristina ^a   Sánchez Galán, Eva ^a   Blanco Colio, Luis M ^a   Martín Ventura, Jose L ^a   Tuñón, Jose ^a   Diaz, Cristina ^b   Hernández, Gonzalo ^b   Egido, Jesus ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b PFIZER INC   (United States)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Atherosclerosis; HMG CoA reductase inhibitors; IKK; NF B; Oxidants

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ATORVASTATIN; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; STATINE DERIVATIVE; SUPEROXIDE;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; I-KAPPA B KINASE; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; PRECIPITIN TESTS; PROTEIN-SERINE-THREONINE KINASES; RATS; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 20944435092     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000159042.50488.e5     Document Type: Article

References (43)

1. Brown M, Miller F, Li W, et al. Overexpression of human catalase inhibits proliferation and promotes apoptosis in vascular smooth muscle cells. Circ Res. 1999;85:524-533.
2. Kunsch C, Medford R. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753-766.
3. Roebuck K, Carpenter L, Lakshmirayanan V, et al. Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-I and NF-κB. J Leukoc Biol. 1999;65:291-298.
4. Barnes P, Karin M. Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
5. Zandi E, Karin M. Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. Mol Cell Biol. 1999;19:4547-4551.
6. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem. 1999;274:27339-27342.
7. Regnier C, Song H, Gao X, et al. Identification and characterization of an IkappaB kinase. Cell. 1997;90:373-383.
8. Zandi E, Rothwarf DM, Delhasc M, et al. The IkappaB kinase complex (IKK) contains two kinase subiinits. IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 1997;91:243-252.
9. Woronicz JD, Gao X, Cao Z, et al. IκB kinase-β, NF-κB activation and complex formation with IκB kinase-α and NIK. Science. 1997;278:866-869.
10. Lee FS, Peters RT, Dang LC, et al. MEKKI activates both IkappaB kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci USA. 1998;95:9319-9324.
11. Nakano H, Shindo M, Sakon S, et al. Differential regulation of I kappa B kinase alpha and beta by two upstream kinases. NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase. Proc Natl Acad Sci USA. 1998;95:3537-3542.
12. Nemoto S, Didonato JA, Lin A. Coordinate regulation of IkappaB kinase α and β by two upstream kinases. NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Mol Cell Biol. 1998;18:7336-7343.
13. Lallena MJ, Diaz-Meco MT, Bren G, et al. Activation of IkappaB kinase beta by protein kinase C isoforms. Mol Cell Biol. 1999;19:2180-2188.
14. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
15. Ortego M, Bustos C, Hernández-Presa M, et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261.
16. Bustos C, Hernández-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
17. Hernández-Presa MA, Martín-Ventura JL, Ortego M, et al. Atorvastatin reduces the expresión of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002;160:49-58.
18. Ortego M., Gómez-Hernández A., Bustos C., Blanco-Colio L.M., Hernández-Presa M.A., Tuñón J., Egido J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells. Eur. J. Pharmacol. 2002;448:113-121.
19. Singh R, Singh N, Rastogi S, et al. Antioxidants effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovasc Drugs Ther. 1997;11:575-580.
20. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1993;1165:335-338.
21. Wassmann S, Laufs U, Müller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-305.
22. Takemoto M, Node K, Hironori N, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
23. Suzumura K, Tanaka K, Yasuhara M, et al. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein. Biol Pharm Bull. 2000;23:873-878.
24. Chen L, Haught WH, Yang B, et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol. 1997;30:569-575.
25. Yilmaz MI, Baykal Y, Kilic M, et al. Effects of statins on oxidative stress. Biol Trace Elem Res. 2004;98:119-127.
26. Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via Snitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856-861.
27. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis. 2004;15:251-258.
28. Bandoh T, Sato EF, Mitani H, et al. Antioxidative potential of fluvastatin via the inhibition of nic otinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Biol Pharm Bull. 2003;26:818-822.
29. Blanco-Colio LM, Tunon J, Martin-Ventura JL, et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63:12-23.
30. Scalia R, Gooszen ME, Jones S, et al. L., Smith MB, Lefer AM, Lefer DJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoproein E-deficient mice. Circulation. 2001;103:2598-2603.
31. Griendling K, Minieri C, Ollerenshaw J, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth cells. Circ Res. 1994;74:1141-1148.
32. Ruiz-Ortega M, Lorenzo O, Rupercz M, et al. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Rex. 2000;86:1266-1272.
33. Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensin converting enzyme inhibition prevents arterial NF-κB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532-1541.
34. Li N, Karin M. Is NF-κB the sensor of oxidative stress? FASEB J. 1999;13:1137-1143.
35. Rossi A, Kapahi P, Natoli G, et al. Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature. 2000;403:103-108.
36. Alpert D, Vilcek J. Inhibition of IkappaB kinase activity by sodium salic ylate in vitro does not reflect its inhibitory mechanism in intact cells. J Biol Chem. 2000;275:10925-10929.
37. Xiong S, She H, Takeuchi H, et al. Signaling role of intracellular iron in NF-κB activation. J Biol Chem. 2003;278:17646-17654.
38. Spencer W, Kwon H, Crépieux P, et al. Taxol selectively blocks microtubule dependent NF-κB activation by phorbol ester inhibition of IκBα phosphorylation and degradation. Oncogene. 1999;18:495-505.
39. Wang W, Passaniti A. Extracellular matrix inhibits apoptosis and enhances endothelial cell differentiation by a NF-kappaB-dependent mechanism. J Cell Biochem. 1999;73:321-331.
40. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.
41. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83:490-500.
42. O'Mahony A, Lin X, Geleziunas R, et al. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol. 2000;20:1170-1178.
43. Dhawan P, Richmond A. A novel NF-κB inducing kinase-MAPK signaling pathway up-regulates NF-κB activity in melanome cells. J Biol Chem. 2002;277:7920-7928.